Results 1 to 10 of about 1,993 (117)
Combination Therapies with PRRT
Pharmaceuticals, 2021 Peptide receptor radionuclide therapy (PRRT) is a successful targeted radionuclide therapy in neuroendocrine tumors (NETs). However, complete responses remain elusive.
Anna Yordanova, Hojjat Ahmadzadehfar
exaly +4 more sources
The Safety and Efficacy of the Repeated PRRT with [90Y]Y/[177Lu]Lu-DOTATATE in Patients with NET
International Journal of Endocrinology, 2021 Purpose. The peptide receptor radionuclide therapy (PRRT) is a treatment option for patients with disseminated, inoperable G1 and G2 neuroendocrine tumours (NETs).
Anna Zemczak +8 more
doaj +2 more sources
Challenges in Von Hippel–Lindau’s disease: PRRT in patients on hemodialysis [PDF]
Endocrinology, Diabetes & Metabolism Case Reports, 2022 Von Hippel–Lindau’s disease (VHL) is a hereditary tumor syndrome characterized by its prototype lesions, hemangioblastomas, and renal cell carcinomas. Treatment for renal cell carcinomas can ultimately result in long-term dialysis.
N Ayub +4 more
doaj +2 more sources
Pharmaceutics, 2022 Aim: The most suitable method for assessment of response to peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NET) is still under debate. In this study we aimed to compare size (RECIST 1.1), density (Choi), Standardized Uptake Value (
Alexander Daniel Jacques Baur +2 more
exaly +3 more sources
Recent Therapeutic Advances in Pituitary Carcinoma [PDF]
Journal of Immunotherapy and Precision Oncology, 2023 Pituitary carcinoma (PC) is a rare, aggressive malignancy that comprises 0.1–0.2% of all pituitary tumors. PC is defined anatomically as a pituitary tumor that metastasizes outside the primary intrasellar location as noncontiguous lesions in the central ...
Ian J. Robertson +4 more
doaj +1 more source
Journal of Pancreatology, 2023 The clinical use of nuclear medicine imaging and therapy in pancreatic neuroendocrine tumors has been greatly strengthened since the approval of 68Ga-DOTATATE and 177Lu-DOTATATE. However, many aspects are still under discussion.
Wenjia Zhu, Meixi Liu, Li Huo
doaj +1 more source
Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours
Cancer Medicine, 2021 Peptide receptor radionuclide therapy (PRRT) is an increasingly used treatment for unresectable neuroendocrine tumours (NETs) that express somatostatin receptors.
Marianne S. Elston +13 more
doaj +1 more source
World Journal of Nuclear Medicine, 2021 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) alone has lesser potential in the clinical setting of neuroendocrine tumor (NET) with large bulky disease and nonhomogeneous somatostatin receptors (SSTR) distribution, owing to lower energy ...
Rahul Parghane +5 more
doaj +1 more source
Application of FLIC model to predict adverse events onset in neuroendocrine tumors treated with PRRT
Scientific Reports, 2021 To develop predictive models of side effect occurrence in GEPNET treated with PRRT. Metastatic GEPNETs patients treated in our centre with PRRT (177Lu-Oxodotreotide) from 2019 to 2020 were considered.
F. Scalorbi +12 more
doaj +1 more source
Diagnostics, 2020 The NETTER-1 study has proven peptide receptor radionuclide therapy (PRRT) to be one of the most effective therapeutic options for metastatic neuroendocrine tumors (NETs), improving progression-free survival and overall survival.
Virginia Liberini +10 more
doaj +1 more source